Barely Significant
← all excerpts

Sunitinib re-challenge in advanced renal-cell carcinoma.

Br J Cancer · 2014 · PMC4453836 · PMID 24800947

Europe PMCDOI
1
hedged sentence
0.0510
closest p · 1.0× alpha
0.0510
boldest claim

The sentences

of borderline significanceP =0.051so close (0.05 < p ≤ 0.1)
This trial demonstrated that the use of sunitinib in treatment-naïve patients with metastatic clear-cell RCC resulted in significant improvements in median progression-free survival (PFS; 11 vs 5 months; P <0.001) and objective response rate (ORR; 47% vs 12% P <0.001) compared with IFN- α , while overall survival (OS) was of borderline significance (26.4 vs 21.8 months; P =0.051); the study had not been designed to demonstrate any OS benefit ( Motzer et al , 2009 ).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.